On October 8, 2024, Barbara Weber, Director at Revolution Medicines Inc (RVMD, Financial), sold 5,200 shares of the company at a price of $48.02 per share. The transaction was documented in a recent SEC Filing. Following this transaction, the insider now owns 13,065 shares of Revolution Medicines Inc.
Revolution Medicines Inc is focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious cancer pathways, particularly the RAS and mTOR signaling pathways. This approach is designed to empower cancer patients with more effective treatment options.
Over the past year, the insider transaction history at Revolution Medicines Inc shows a total of 46 insider sells and no insider buys. This pattern of transactions suggests a trend where insiders are choosing to sell shares more than purchasing them.
As of the latest sale, shares of Revolution Medicines Inc were trading at $48.02, giving the company a market cap of approximately $8.27 billion. The stock is currently considered to be Significantly Overvalued according to the GF Value, with a price-to-GF-Value ratio of 106.71.
The GF Value is a proprietary measure used to determine the fair value of a stock, taking into account historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with an adjustment factor based on past returns and growth, and future business performance estimates from analysts.
This recent insider sell by Barbara Weber might provide investors with interesting insights into the current valuation and future prospects of Revolution Medicines Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
